Thursday, December 19, 2013
A Novartis AG-University of California, San Diego-led consortium has identified a new class of
antimalarials that, unlike marketed drugs, eliminates Plasmodium at all
stages of its infection cycle.1 The pharma is developing derivatives
of the lead inhibitor with improved drug-like properties.
Boettner, B. SciBX 6(48); doi:10.1038/scibx.2013.1373
Published online Dec. 19, 2013
1. McNamara, C.W. et
al. Nature; published online Nov. 27, 2013; doi:10.1038/nature12782
Contact: Elizabeth A. Winzeler, University of California, San Diego, La
Contact: Thierry T. Diagana, Novartis Institute for Tropical Diseases,
2. Wells, T.N.C. et al.
Nat. Rev. Drug Discov. 8, 879-891 (2009)
AND INSTITUTIONS MENTIONED
Genomics Institute of the Novartis Research Foundation, San Diego, Calf.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Medicines for Malaria Venture, Geneva, Switzerland
National Institute of Allergy and Infectious Diseases, Bethesda, Md.
National Institutes of Health, Bethesda, Md.
Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland
Novartis Institute for Tropical Diseases, Singapore
(Euronext:SAN; NYSE:SNY), Paris, France
Sigma-Tau Group, Pomezia, Italy
University of California, San Diego, La Jolla, Calif.